Live Trading News
Live Financial News
  • facebook
  • twitter
  • google_plus
  • Email

China Resources Double-Crane Pharmaceutical (600062:SS) Is A Buy

By HEFFX on November 26, 2020

$600062 #ChinaResourses #DoubleCrane #Pharmaceutical #HEFFX

China Resources Double-Crane Pharmaceutical
Ticker: 600062:SS
Price: CNY12.54
Recommendation: Buy

Join Knightsbridge Live affiliate program and for every referral, you earn a bonus of up to $20,000 plus free trades. The best way to earn extra income!

Business Summary

CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals.

The Company’s main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment.

Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional.

The Company distributes its products mainly in domestic market.

Price Performance

Relative Valuation

Technical Indicators

Overall, the bias in prices is: Downwards.

The projected upper bound is: 12.86.

The projected lower bound is: 12.20.

The projected closing price is: 12.53.

Candlesticks

A white body occurred (because prices closed higher than they opened).
During the past 10 bars, there have been 4 white candles and 6 black candles for a net of 2 black candles. During the past 50 bars, there have been 19 white candles and 30 black candles for a net of 11 black candles.

Momentum Indicators

Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.

Stochastic Oscillator

One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 11.8183. This is an oversold reading. However, a signal is not generated until the Oscillator crosses above 20 The last signal was a buy 8 period(s) ago.

Relative Strength Index (RSI)

The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 39.15. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a sell 90 period(s) ago.

Commodity Channel Index (CCI)

The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is -136.This is an oversold reading. However, a signal isn’t generated until the indicator crosses above -100. The last signal was a sell 11 period(s) ago.

MACD

The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a sell 4 period(s) ago.

Rex Takasugi – TD Profile

RESOUR D-C PHARM closed up 0.030 at 12.540. Volume was 53% below average (consolidating) and Bollinger Bands were 48% narrower than normal.

Open    High     Low    Close     Volume
12.500  12.580   12.480 12.540    3,990,387
Technical Outlook
Short Term:        Oversold
Intermediate Term: Bearish
Long Term:         Bearish
Moving Averages: 10-period    50-period    200-period
Close:           12.71        12.84        13.20
Volatility:      13           16           28
Volume:          6,430,022    4,745,493    10,115,830

Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.

Summary

RESOUR D-C PHARM is currently 5.0% below its 200-period moving average and is in an downward trend. Volatility is relatively normal as compared to the average volatility over the last 10 periods.

Our volume indicators reflect volume flowing into and out of 600062.SS at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bearish on 600062.SS and have had this outlook for the last 3 periods.

  #(600062:SS), #best fx account, #best fx company, #best trading platform, #China Resources Double-Crane Pharmaceutical, #daily stock brief Heffx, #Make money trading with Heffx, #morning call with Heffx, #open an account fx, #Shayne Heffernan well known economist Asia, #trade like Shayne Heffernan

China Resources Double-Crane Pharmaceutical (600062:SS) Is A Buy added by HEFFX on November 26, 2020
View all posts by HEFFX →

The following two tabs change content below.
  • Bio
  • Latest Posts

HEFFX

HEFFX has become one of Asia’s leading financial services companies with interests in Publishing, Private Equity, Capital Markets, Mining, Retail, Transport and Agriculture that span every continent of the world. Our clearing partners have unprecedented experience in Equities, Options, Forex and Commodities brokering, banking, physical metals dealing, floor brokering and trading.

Latest posts by HEFFX (see all)

  • Tesla Is Hiring Someone To Defend Elon Musk And Fend Off Attacks By Twitter Trolls - January 20, 2021
  • PayPal Will Continue To Profit From A Huge Increase In Volume And Accounts - January 20, 2021
  • Google’s Ethical AI Division Investigating Sharing of Sensitive Documents - January 20, 2021

Related posts:

  1. Australian Dollar: USD/AUD (AUD=X) Further escalation in Australia – China tensions
  2. China World Trade Center (600007:SS) HEFFX Target Price CNY20.00
#(600062:SS)#best fx account#best fx company#best trading platform#China Resources Double-Crane Pharmaceutical#daily stock brief Heffx#Make money trading with Heffx#morning call with Heffx#open an account fx#Shayne Heffernan well known economist Asia#trade like Shayne Heffernan
  • Asia
  • China
  • Headline News
  • Health
  • Investments
  • Shayne Heffernan
  • Shayne Heffernan
  • Top Stories
Share
Related Posts

Commentary: Paul Ebeling on Wall Street

Sitting on a Cash Pile 10.0? Online Sports Gambling Appears a Good Bet

Wall Street’s Key Stock Analysts Research Report, All Buys

Monday’s World Stock Markets: Asia-Pacific

Afraid of COVID-19? Think Prevention

Insiders and Hedge Funds Seen Buying Ferrari (NYSE:RACE) Shares

‘The Marksman’ Toped Weekend Box Office with Only $2-M

  • About US
  • Calendar
  • Contact Us
    • Contributors
    • Privacy Policy
  • Free Trial
  • IR
  • Live Charts
View Desktop Version